

Predicting the transmission of COVID-19 using inter and intra-county mobility: a mathematical modelling study

Blair Yang

August 2022

Style

[REF] Pending reference, with the following URL

[REF] Pending reference, with the following URL

[REF] Pending reference, with un-specified topic (need to find relevant papers)

<DATA> Pending data, need to be filled with data from the cited papers

<DATA> Pending data, need to be find relevant paper with such data

<FIGURE> Pending main figure, need to be add a major figure for this section

<FIGURE> Pending supplementary figure, need to be add a supplementary figure in the supplementary material section for this section

1 Supplementary analysis




Figure S1: Relative effectiveness of natural, vaccine, and hybrid immunity.




Figure S1: Estimating the effectiveness of 2 and 3 doses of vaccination against clinical infection of the omicron variant of SARS-Cov-2.

2 Methodology (supplementary material)




Figure 1: The epidemiological compartmental model. The transmission (infection) was divided into two stages: workplace and school, and household and others. **A).** Data calibration using time-series forecast. The Ontario-specific google mobility index, vaccination status, and

current ratio of VOCs, were sent into a MLP network to forecast the trend in the following three years. **B).** The age-specific effective contact matrix synthesized from the relevant data output from the MLP network by categories. **C).** The susceptible compartment of the SEIR(S) model, stratified into 528 subgroups according to demographical data. The susceptible individuals in 528 counties will be redistributed by the starting of time-step 1 at the beginning of each transmission cycle due to commutation and will be restored by time-step 5. We assumed all of the removed individuals will be moved into the susceptible group 15 days after recovery with immunity (waning). **D).** The exposed and infected compartment of the model during the workplace and school transmission cycle. This stage uses synthesized workplace and school contact matrix, after redistribution due to commutation. **E).** The he exposed and infected compartment of the model during the household and others transmission cycle. This stage uses synthesized residence and others contact matrix, after restoration of commutation. **F).** The removed stage of the compartmental model. We assumed all of the recovered individuals will be move to susceptible state 15 days after recovery due to immunity waning. The recovered individual still has shielding immunity against infection.

2.1 Data source

2.1.1 Demographic of Ontario

We stratified the population in Ontario into 26 public health units (PHU), **<DATA>** districts, and 528 counties, and 16 age bands, according to the 2016 Canadian demographics census **[REF]**. Our model... . The pool of susceptible individuals was divided into 528 counties, administrated by 26 PHUs. We assumed a uniform incidence rate for the counties within the same PHU at on the first day of the modelling.

2.1.2 Epidemiological data

We acquired the time-series data of COVID-19 cases, deaths, and vaccination data in the 26 Public health units (PHU) since January 2020 from Ontario public health. **[1]** The original data was stratified into **<DATA>** age bands (**<DATA>**).

2.1.3 Vaccine data

We acquired the provincial time-series vaccination data in Ontario from Ontario public health, covering the percentage population who has taken first does, second dose, and third does. We assumed a uniform distribution of the vaccination ratio for every PHU.

2.1.4 Labour force data

We used the labour force age distribution of Canada from **[REF] (2016 Census)** in year **<DATA>** and the employment rate in August 2022 **<DATA>** by statistics Canada **[REF]**.

2.1.5 Commute data

The commuting matrix in Ontario was excerpted from the 2016 demographic census. We assumed a uniform age distribution across the province, and adjusted the number of commuters by **<DATA>** due to the change in employment rate (**<DATA>**).

2.1.6 Population mobility data

We used the population mobility data from Google. **[REF]** The data was categorized into 5 groups: grocery and pharmacy, residential, retail and recreation, transit, and workplaces. To address the fluctuation of the population mobility, we used a multi-layer perceptive model (MLP) from Keras to forecast the population mobility in the next 1000 days since August 23rd, 2022. **[6] [REF]**

2.2 Data Calibration

2.2.1 Age-specific data calibration

Due to the different dimensionality of the contact matrix in Canada (16 age-bands with 5-years sensitivity) and the Ontario epidemiological data (6 age-bands with 10-years sensitivity), we augmented all of the age-specific data using difference of Gaussians (DoG), the estimated percentage population with certain characteristic (i.e, cases, deaths, vaccinated) with an integer-valued age i is estimated to be:

$$\mu_i = \Gamma_{\sigma_1, \sigma}(i) = \frac{e^{-\frac{i^2}{2\sigma_1^2}}}{\sigma_1 \sqrt{2\pi}} I - \frac{e^{-\frac{i^2}{2\sigma_2^2}}}{\sigma_2 \sqrt{2\pi}} I = \sum_{\mu \in I} \frac{e^{-\frac{(i-\mu_1)^2}{2\sigma_1^2}}}{\sigma_1 \sqrt{2\pi}} \mu_2 - \frac{e^{-\frac{(i-\mu_1)^2}{2\sigma_2^2}}}{\sigma_2 \sqrt{2\pi}} \mu_2 \quad (1)$$

Where i is a positive integer which denotes to the age of distribution, I denotes to the set of the raw age distribution with a 10-years age sensitivity, σ_1, σ_2 denotes to two positive constants, $\mu = (\mu_1, \mu_2)$ is a tuple with the median age of the age band and percentage distribution at 1st and 2nd entry, respectively. We then integrated the age of each six age bands.

2.2.2 Prevalence calibration

Source suggested that there are significant underascertainment of the number of cases and deaths of COVID-19 in Canada. **[2] [3]** We calculated the average of the underascertainment ratio of **<DATA>** and assumed the ratio to be constant throughout the pandemic.

2.2.3 Vaccine immunity level estimation

Khoury and Menni suggested that the predictability of the immunity waning effect of COVID-19 vaccine. **[4] [5]** Menni's model gave an insight into the age-group specific vaccine efficacy of the most prevalence vaccines in Ontario, BNT162b2 and mRNA1273mm against infection for up to eight months. Khoury's model gave an estimation of the longer-term waning effect of the vaccine efficacy against both mild and severe symptoms. We **combined two models** for both short-term and long-term accuracy. **<FIGURE>**, **<FIGURE>**.

Ontario has announced its plan for third boost dose. ... We also

2.3 Differential equations for the model

$$\begin{aligned}
 & \left\{ \begin{aligned}
 dS(t) &= -\sum_{x \in C} (m_x \beta_0 \circ (1_{16} - \mu)(M^x)^T (I_{t,c} + 0.5I_{t,s})) \\
 dE(t) &= \sum_{x \in C} (m_x \beta_0 \circ (1_{16} - \mu)(M^x)^T (I_{t,c} + 0.5I_{t,s})) - dI \\
 dI_s(t) &= \sum_{d \leq t} (\nu \circ E_d \sigma(t-d) - \gamma_s I_s) - dR_s(t) \\
 dI_c(t) &= \sum_{d \leq t} ((1_{16} - \nu) \circ E_d \sigma(t-d) - \gamma_s I_s) - dR_c(t) \\
 dI_{hosp}(t) &= \left(\sum_{d \leq t} I_{i,d} h(i) (1 - g(i)) T_{hosp}(t-d) \right)_i^{i \in \text{age bands}} \\
 dI_{ICU}(t) &= \left(\sum_{d \leq t} I_{hosp,d} g(i) T_{ICU}(t-d) \right)_i^{i \in \text{age bands}} \\
 dI_{non-hosp}(t) &= dI_c - dI_{hosp,t} - dI_{ICU,t} - dR_{ICU} \\
 dI(t) &= dI_s(t) + dI_{non-hosp}(t) + dI_{hosp}(t) + dI_{ICU}(t) \\
 dR_s(t) &= \sum_{d \leq t} I_s \gamma_s(t-d) \\
 dR_{non-hosp}(t) &= \sum_{d \leq t} I_{non-hosp} \gamma_{non-hosp}(t-d) \\
 dR_{hosp}(t) &= \sum_{d \leq t} I_{hosp} \gamma_{hosp}(t-d) \\
 dR_{ICU}(t) &= \sum_{d \leq t} I_{ICU} \gamma_{ICU}(t-d) \\
 dR(t) &= dR_s(t) + dR_{non-hosp}(t) + dR_{hosp}(t) + dR_{ICU}(t) \\
 dD(t) &= cfr \circ dR(t) \\
 dr(t) &= (1_{16} - cfr) \circ dR(t) \\
 \mu_{t,v,s} &= \frac{\sum_{d \leq t} V_d \varphi(t-d) \mu_{0,v,s}}{P} \\
 \mu_{t,n,s} &= \frac{\sum_{d \leq t} I_d \varphi(t-d) \mu_{0,v,s}}{P} \\
 \mu_{t,s} &= \frac{\sum_{d \leq t} I_d \varphi(t-d) \mu_{0,v,s} + \sum_{d \leq t} V_d \varphi(t-d) \mu_{0,v,s}}{P} \\
 cfr &= cfr_0 \circ \mu_{t,s}
 \end{aligned} \right. \\
 & \left\{ \begin{aligned}
 out_{c,t,I} &= I_{c,t} \circ w \\
 out_{c,t,S} &= S_{c,t} \circ w \\
 OUT_{c,t,I} &= \left(\frac{C_{i,j}}{\text{sum}(C_i)} out_{c,t,I} \right)_j^{j \in \{1, \dots, 528\}} \\
 OUT_{c,t,S} &= \left(\frac{C_{i,j}}{\text{sum}(C_i)} out_{c,t,S} \right)_j^{j \in \{1, \dots, 528\}}
 \end{aligned} \right.
 \end{aligned}$$

Epidemiological

Commutational

2.4 Parameters

Table 1: Epidemiological convolutional kernels in the model as probability distributions

Parameter	Description	Value	Reference
d_E	Latent period (E to I_p and E to I_s)	$\sim \text{gamma}(2.5, 4)$	Davies et al.
d_c	Duration of clinical infectiousness	$\sim \text{gamma}(2.5, 4)$	Davies et al.
d_s	Duration of sub-clinical infectiousness	$\sim \text{gamma}(5, 4)$	Davies et al.
d_{pos}	Duration of PCR positivity	$\sim \text{normal}(9.87, 0.25)$	[REF]
d_{hosp}	Duration from PCR positivity to hospitalization	$\sim \text{normal}(7.5, 1)$	Davies et al.
d_{ICU}	Duration from hospitalization to ICU	$\sim \text{normal}(3.6, 1)$	Davies et al.
$d_{R,hosp}$	Average stay in hospital	$\sim \text{normal}(11.08, 1.2)$	Davies et al.
$d_{R,ICU}$	Average stay in hospital	$\sim \text{normal}(13.33, 1.2)$	Davies et al.

Table 2: Age-specific odds

Parameter	Description	Value	Reference
$susc_ratio$	Relative susceptibility to infection by age	0.39 - 0.86	Davies et al.
$clin_ratio$	Clinical fraction by age	0.23 - 0.71	Davies et al.
$hosp_ratio$	Hospitalization ratio of clinical cases by age	0.009 - 0.21	[REF]
icu_ratio	ICU hospitalized ratio of clinical cases by age	0.001 - 0.028	[REF]
cfr_ratio	Case-fatality ratio by age	0.00009 - 0.09	[REF]
$work_ratio$	Working force ratio by age	DoG interpolation	[REF]
sch_ratio	School ratio by age	DoG interpolation	[REF]

$$P(Hosp|Clinical) = /$$

We defined following variables with their corresponding meaning. Each variable is a real-valued function $\cdot : \text{date} \rightarrow \mathbb{R}^+$.

- $S :=$ Number of susceptible individuals
- $E :=$ Number of exposed individuals
- $I :=$ Number of infected individuals
- $I_s :=$ Number of subclinical infected individuals
- $I_p :=$ Number of preclinical infected individuals
- $I_c :=$ Number of clinical infected individuals
- $I_h :=$ Number of hospitalized infected individuals
- $I_{ICU} :=$ Number of ICU-hospitalized infected individuals
- $R :=$ Number of removed individuals
- $r :=$ Number of recovered individuals
- $D :=$ Number of deceased individuals

We define the following notations to represent the change of variables:

- $\Delta \cdot :=$ Number of individuals transformed into a specific state within a time step
- $\delta \cdot :=$ Number of individuals transformed out from a specific state within a time step
- $d \cdot :=$ change of the number of individuals transformed out from a specific state within a time step

We define the following transition functions:

Susceptible to exposed

$$\Delta E(t) = \text{ratio} \circ M^x I(x)$$

$$\Delta S(t) = \overbrace{(\Delta R(t) - \Delta D(t))}^{=\Delta r(t)}$$

$$\delta S(t) = -\Delta E(t)$$

$$dS(t) = \Delta S(t) - \delta S(t) = \overbrace{(\Delta R(t) - \Delta D(t))}^{=\Delta r(t)} - \Delta E$$

Exposed to infected

Exposed to subclinical infection

$$\begin{aligned}\Delta I_s(t) &= (E * f_{d_s})(t) \circ (1_{16} - clin_ratio) \\ \delta I_s(t) &= (I_s * f_{d_s})(t)\end{aligned}$$

Exposed to pre-clinical infection

$$\begin{aligned}\Delta I_p(t) &= (E * f_{d_p})(t) \circ clin_ratio \\ \delta I_p(t) &= (I_p(t) * f_{d_c})(t)\end{aligned}$$

Exposed to all-type of infected individuals

$$\begin{aligned}\Delta I &= \Delta I_s + \Delta I_p \\ \delta I &= \delta I_s + \delta I_p \\ dS(t) &= (\Delta I_s + \Delta I_p) - (\delta I_s + \delta I_p)\end{aligned}$$

Transition within infected

Pre-clinical infection to clinical infection

$$\begin{aligned}\Delta I_c &= (I_p * f_{d_c})(t) \\ \delta I_c &= (I_c * f_{d_{pos}})(t)\end{aligned}$$

References

- [1] Public Health Ontario. Ontario COVID-19 Data Tool. Datasets - ontario data catalogue. Retrieved August 21, 2022, from <https://data.ontario.ca/en/dataset?groups=2019-novel-coronavirus>
- [2] Bolotin, S., Tran, V., Deeks, S. L., Peci, A., Brown, K. A., Buchan, S. A., Ogbulafor, K., Ramoutar, T., Nguyen, M., Thakkar, R., Delacruz, R., Mustfa, R., Maregmen, J., Woods, O., Krasna, T., Cronin, K., Osman, S., Joh, E., & Allen, V. G. (2021). Assessment of population infection with SARS-COV-2 in Ontario, Canada, March to June 2020. *Euro-surveillance*, 26(50). <https://doi.org/10.2807/1560-7917.es.2021.26.50.2001559>
- [3] Anand, S. S., Arnold, C., Bangdiwala, S. I., Bolotin, S., Bowdish, D., Chanchlani, R., de Souza, R. J., Desai, D., Kandasamy, S., Khan, F., Khan, Z., Langlois, M.-A., Limbachia, J., Lear, S. A., Loeb, M., Loh, L., Manoharan, B., Nakka, K., Pelchat, M., Wahi, G. (2022). Seropositivity and risk factors for SARS-COV-2 infection in a South Asian community in Ontario: A cross-sectional analysis of a prospective cohort study. *CMAJ Open*, 10(3). <https://doi.org/10.9778/cmajo.20220031>

- [4] Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine*. <https://doi.org/10.1038/s41591-021-01377-8>
- [5] Menni, C., May, A., Polidori, L., Louca, P., Wolf, J., Capdevila, J., Hu, C., Ourselin, S., Steves, C. J., Valdes, A. M., & Spector, T. D. (2022). Covid-19 vaccine waning and effectiveness and side-effects of boosters: A Prospective Community study from the Zoe Covid Study. *The Lancet Infectious Diseases*, 22(7), 10021010. [https://doi.org/10.1016/s1473-3099\(22\)00146-3](https://doi.org/10.1016/s1473-3099(22)00146-3)
- [6] <https://github.com/keras-team/keras>
- [7] 10.1001/jama.2022.2274